6,7-Dihydroxy-3-phenylcoumarin inhibits thromboplastin induced disseminated intravascular coagulation

British Journal of Haematology

Volumn 126, Issue 2, 2004, Pages 226-230

  Tunali, Tugba ^a   Yarat, Aysen ^a   Bulut, Mustafa ^a   Emekli, Nesrin ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

6,7 dihydroxy 3 phenylcoumarin; Disseminated intravascular coagulation; Glutathione; Lipid peroxidation; Warfarin

Indexed keywords

6,7 DIHYDROXY 3 PHENYLCOUMARIN; COUMARIN DERIVATIVE; FIBRINOGEN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; FEMALE; FIBRINOLYSIS; LEUKOCYTE COUNT; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; THROMBOCYTE COUNT;

ANIMALS; ANTICOAGULANTS; COUMARINS; DEPRESSION, CHEMICAL; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRINOGEN; LIPID PEROXIDATION; MODELS, ANIMAL; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROTHROMBIN TIME; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; THROMBOPLASTIN; WARFARIN;

EID: 3242674169     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05033.x     Document Type: Article

References (32)

1. Ansell, J., Hirsh, J., Dalen, J., Bussey, H., Anderson, D., Poller, L., Jacobson, A., Deykin, D. & Matchor, D. (2001) Managing oral anticoagulant therapy. Chest, 119, 22S-38S.
2. Baglin, T. (1996) Disseminated intravascular coagulation: diagnosis and treatment. British Medical Journal, 312, 683-686.
3. Beutler, E. (1975) Glutathione: RedCell Metabolism a Manual Biochemical Methods, pp. 112-114. Grune and Stratton, New York.
4. Bick, R.L. (1998) Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Seminars in Thrombosis and Hemostasis, 24, 3-18.
5. Bithell, T.C. (1993) Acquired coagulation disorders. In: Wintrobe's Clinical Hematology (ed. by G.R. Lee, T.C. Bithell, J. Forester, J.W. Athens, J.N. Lukens), pp. 1480-1494. Lea & Febiger, London.
6. Gitel, S.N. & Wessler, S. (1979) The antithrombotic effects of Warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications. The Journal of Laboratory and Clinical Medicine, 94, 481-488.
7. Harrison, L., Johnston, M., Massicotte, M.P., Crowther, M., Moffat, K. & Hirsh, J. (1997) Comparison of 5 mg and 10 mg loading doses in initiation of Warfarin therapy. Annals of Internal Medicine, 126, 133-136.
8. Hathcock, J. (2004) Vascular biology - the role of tissue factor. Seminars in Hematology, 41, 30-34.
9. Hirsh, J. & Valentin, F. (1994) Guide to anticoagulant therapy. Part 2: oral anticoagulants. Circulation, 89, 1469-1480.
10. Imanishi, N., Komuro, Y. & Morooko, S. (1991) Effect of a selective PAF antagonist SM-10661((±)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC). Lipids, 26, 1391-1395.
11. Levi, M. & Ten Cate, H. (1999) Disseminated intravascular coagulation. The New England Journal of Medicine, 341, 586-592.
12. Mammen, E.F. (1971) Purification of tissue thromboplastin. In: Thrombosis and Bleeding Disorders (ed. by N. Bong, F.K. Beller, E. Deutsch, E.F. Mammen), pp. 169-171. Academic Press, New York, London.
13. Marwaha, R.K., Mitra, S. & Marwaha, N. (1998) Disseminated intravascular coagulation: pathophysiology and principles of management. Indian Pediatrics, 35, 243-251.
14. Matsuda, T. (1996) Clinical aspects of DIC. Polish Journal of Pharmacology, 48, 73-75.
15. Meza, L.A., Green, M.D., Hackett, J.R., Neumann, T.A. & Holmes, F.A. (2003) Filgrastim-mediated neutrophil recovery in patients with breast cancer treated wirh docetaxel and doxorubicin. Pharmacotherapy, 23, 1424-1431.
16. Oldham, K.M. & Bowen, P.E. (1998) Oxidative stress in critical care: is antioxidant supplementation beneficial? Journal of American Dietetic Association, 98, 1001-1008.
17. Rickles, F.R., Patierno, S. & Fernandez, P.M. (2003) Tissue factor, thrombin and cancer. Chest, 124 (Suppl 3), 58-68.
18. Roberts, H.R., Monroe, D.M. & Macreane, H. (2001) Molecular biology and biochemistry of the coagulation factor and pathways of hemostasis. In: Williams Hematology (eds by E. Beutler, M.A. Lichtman, B.S. Coller, T.J. Kipps, U.R.I. Seligsohn), pp. 1409-1434. McGraw-Hill, USA.
19. Ross, D. (1998) Glutathione, free radicals and chemotherapeutic agents. Pharmacology and Therapeutics, 37, 231-249.
20. Salvemini, D. & Cuzzocrea, S. (2002) Oxidative stress in septic shock and disseminated intravascular coagulation. Free Radical Biology and Medicine, 33, 1173-1185.
21. Selighsohn, U. (2001) Disseminated intravascular coagulation (DIC). In: Williams Hematology (ed. by E. Beutler, M.A. Lichtman, B.S. Coller, T.J. Kipps, U.R.I. Seligsohn), pp. 1677-1695. McGraw-Hill, USA.
22. Tanabe, K., Terada, Y., Shibutani, T., Kunitada, S. & Kondo, T.A. (1999) Specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor-induced disseminated intravascular coagulation in rats. Thrombosis Research, 96, 135-143.
23. Uchiba, M., Okajima, K., Murakami, K., Johna, M., Okabe, H. & Tokatsuki, K. (1997) Effect of human urinary thrombomodulin on endotoxin induced intravascular coagulation and pulmonary vascular injury in rats. American Journal of Hematology, 54, 118-123.
24. Vad, H., Tuedskov, T.F. & Hansen, K.B. (1997) Anticoagulant properties of rabbits lungs in tissue thromboplastin induced intravascular coagulation. Thrombosis and Haemostasis, 77, 679-684.
25. Wada, H., Otsu, A., Takesue, Y., Sagara, K. & Makita, T. (1984) Effect of TEI-4120 (3-benzoyl-N-beta-ethoxvisopropyl-2-methylinndole) on carrageenan induced disseminated intravascular coagulation in rats. Journal of Pharmacobio-dynamics, 7, 385-391.
26. Weidenbörner, M. & Jha, H.C. (1995) 3-phenyl coumarins as antifungal substances against four seed contaminating moulds. Chemie Microbiologie Technologie der Lebensmittel, 17, 22-24.
27. Weiss, P., Soff, G.A., Halkin, H. & Seligsohn, U. (1987) Decline of protein C and protein S and factors II, VII, IX and X during the initiation of Warfarin therapy. Thrombosis Research, 45, 783-790.
28. WHO Expert Committee on Biological Standardization (1983) WHO Expert Committee on Biological Standardization. Thirty-third Report, Technical Report Series 687. WHO, Geneva, Switzerland.
29. WHO Expert Committee on Biological Standardization (1999) WWO Expert Committee on Biological Standardization. Forty-eighth Report, Biological Series 889, WHO, Geneva, Switzerland.
30. Yagi, K. (1984) Assay for blood plasma or serum methods in enzymology. Methods in Enzymology, 105, 328-337.
31. Yamazaki, M., Asakura, H., Aoshima, K., Saito, M., Jokaji, H., Votani, C., Kumbashari, I., Murishita, E., Ilkeda, T. & Matsuda, T. (1994) Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of FXa, against experimental DIC in rats. Thrombosis Research, 72, 392-396.
32. Yoshikawa, T., Murakami, M., Furukawa, Y., Kato, H., Takemura, S. & Kondo, M. (1983) Lipid peroxidation and experimental disseminated intravascular coagulation in rats induced by endotoxin. Thrombosis and Haemostasis, 49, 214-216.